After FDA rebuff, Celgene on track to refile ozanimod—in 2019

Celgene
The delay is a blow to a potential blockbuster that would, with a better safety profile, rival Novartis’ Gilenya. (Celgene)

Celgene suffered an embarrassing setback in February when it got a refuse-to-file letter for its multiple sclerosis drug ozanimod. Now, the company says, it expects to resubmit the NDA in the first quarter of 2019, delaying its timeline by a year.

The delay is a blow to a potential blockbuster that would, with a better safety profile, rival Novartis’ Gilenya. Celgene will have to wait a little longer to start reaping sales that could reach $5 billion a year. But it could be worse—while the 2019 timeframe isn’t great, it is still “better than worst fears of 2020 refiling and long delay,” wrote Jefferies analysts in a note to investors.

“Key questions will be around what FDA wanted for refiling (likely two-year animal cancer carcinogenicity studies due to new metabolite found at high levels in humans),” the analysts said.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The FDA sent the refuse-to-file notice because the Celgene failed to provide the necessary preclinical and clinical pharmacology information on ozanimod. At the time, management explained that the letter was not related to concerns about S1P receptor modulators and said it thought it could use existing activities to address some of the agency’s feedback.

RELATED: Celgene’s big hope ozanimod lowers pMS score in long-term ulcerative colitis

While Celgene was optimistic, the impact of the FDA’s refusal and the ensuing delay could extend beyond ozanimod’s immediate future. It may also color perceptions of Celgene and confidence in its ability to deliver in the coming years.

“This just adds even more uncertainty and credibility questions, which is not helpful right now given Celgene is in a period where they need to instill confidence after the recent disappointments,” wrote Jefferies analyst Michael Yee in February.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.